Bertagnolli raises paylines, creates Clinical Trials Innovation Unit, and announces National Cancer Plan

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care.

September 06, 2024

Vol.50 No.33

In Brief

Hawai’i’s Michele Carbone, Haining Yang receive $2.5M NCI grant for mesothelioma research

Michele CarboneHaining YangMichele Carbone and Haining Yang, researchers at the University of Hawai’i Cancer Center, received a $2.5 million NCI grant to advance mesothelioma research by improving diagnosis and treatment for the disease.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC

FDA accepted Bristol Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma.

September 06, 2024

Vol.50 No.33

Bertagnolli raises paylines, creates Clinical Trials Innovation Unit, and announces National Cancer Plan

YOU MAY BE INTERESTED IN

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Hawai’i’s Michele Carbone, Haining Yang receive $2.5M NCI grant for mesothelioma research

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Bertagnolli raises paylines, creates Clinical Trials Innovation Unit, and announces National Cancer Plan

YOU MAY BE INTERESTED IN

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5BRathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Hawai’i’s Michele Carbone, Haining Yang receive $2.5M NCI grant for mesothelioma research

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC

Can you spare 10 minutes to complete a survey?

Login

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”